Showing 4381-4390 of 8735 results for "".
- Study Shows Novel Effects of Eucerin Active Ingredient Complex on Atopic Dermatitishttps://practicaldermatology.com/news/study-shows-novel-effects-of-eucerin-active-ingredient-complex-on-atopic-dermatitis/2458717/Beiersdorf researchers in collaboration with the Dermatological Clinic of the University of Lübeck have shown in a double-blind clinical study that the AtopiControl ingredient complex including licochalcone, a from the licorice root and omega-6 fatty acids from evening primros
- SENTÉ Raises $5 million, Appoints New CEOhttps://practicaldermatology.com/news/sent-raises-5-million-appoints-new-ceo/2458713/There’s big news coming out of SENTÉ this week. Fresh of the announcement that they closed on a $5 million financing round, the company also appointed Laurent Combredet as President and Chief Executive Officer. Mr. Combredet was G
- Meet the Neocutis' Family's Newest Add: Micro-Firm Neck and Décolleté Rejuvenating Complexhttps://practicaldermatology.com/news/meet-the-neocutis-familys-newest-add-micro-firm-neck-and-dcollet-rejuvenating-complex/2458723/Neocutis’ Micro-Firm Neck and Décolleté Rejuvenating Complex is slated to hit physician’s offices in March 2016. The cream, which will be the newest addition to the Neocutis family of anti-aging products, targets the delicate
- New Sunscreen Blocks UV Rays, Boosts Vitamin Dhttps://practicaldermatology.com/news/new-sunscreen-blocks-rays-boosts-vitamin-d/2458724/A new sunscreen may do more than block ultraviolet radiation, it may also allow the body to produce vitamin D. The sunscreen, Solar D, is currently available in Australia and will be available in the U.S. in summer 2016.The
- Dr. Andrew Krakowski Now CMO at DermOnehttps://practicaldermatology.com/news/andrew-krakowski-now-cmo-at-dermone/2458729/Andrew C. Krakowski, MD has joined DermOne, a network of comprehensive dermatology practices, as Chief Medical Officer. “The need for dermatology services has accelerated in recent years, due to an aging population, a growing demand for surgical and cosmetic procedures and a raised
- Novartis Teams with Pro Football Hall of Famer Troy Aikman on Melanoma Educationhttps://practicaldermatology.com/news/novartis-teams-with-pro-football-hall-of-famer-troy-aikman-on-melanoma-education/2458727/Troy Aikman, diagnosed with stage II melanoma in 1998, has teamed up with Novartis for the Melanoma Just Got Personal campaign. The campaign has created personalized markings to show the different mutations of melanoma. Campaign partners are asking patients and supporters to show th
- Surgical Specialties Corporation Acquires FSSB Chirurgische Nadein GMBHhttps://practicaldermatology.com/news/surgical-specialties-corporation-acquires-fssb-chirurgische-nadein-gmbh/2458735/Surgical Specialties Corporation has acquired all shares of FSSB Chirurgische Nadein GMBH (FSSB) and affiliated entities. Terms were not disclosed. The acquisition will be immediately accretive to both Surgical Specialties' sales and adjusted EBITDA. FSSB was founded in 1995 by c
- New Web Tool May Curb Indoor Tanning Use Among Coedshttps://practicaldermatology.com/news/new-web-tool-may-curb-indoor-tanning-use-among-coeds/2458737/A web-based intervention that taps into indoor tanning users’ perceptions about the value of tanning may help curb tanning bed use among young females, suggests research out of Rutgers Cancer Institute of New Jersey in New Brunswick. Research has shown that some indoor tanners do so
- Review Article Shines Spotlight on Neurocutaneous Disordershttps://practicaldermatology.com/news/review-article-shines-spotlight-on-neurocutaneous-disorders/2458739/There are at least 60 genetic neurocutaneous disorders that involve the skin, central nervous system, according to a review article in the Current Neurology and Neuroscience Reports. For example, neurofibrom
- FDA Approves Updated Label for New Dosing Regimen for Allergan's Dalvancehttps://practicaldermatology.com/news/fda-approves-updated-label-for-new-dosing-regimen-for-allergans-dalvance/2458741/The FDA has approved Allergan plc’s supplemental new drug application (sNDA) to update the label for Dalvance® (dalbavancin) for injection. The expanded label will include a single dose administered as a 30-minute intravenous (IV) infusion of Dalvance for the treatment o